Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Monoclonal antibodies to CD4

F C Breedveld1

  • 1Department of Rheumatology, Leiden University Medical Center, The Netherlands. F.C.Breeveld@Rheumatology.MedFac.LeidenUniv

Rheumatic Diseases Clinics of North America
|August 26, 1998
PubMed
Summary

Targeting T-cells with anti-CD4 monoclonal antibodies (CD4-mAb) shows promise for reinducing self-tolerance in autoimmune diseases. These therapies can prevent and suppress disease activity in animal models, including collagen-induced arthritis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preface.

Seminars in arthritis and rheumatism·2019
Same author

Advances in targeted therapies 2017.

Clinical immunology (Orlando, Fla.)·2018
Same author

Advances in targeted therapies XIII.

Annals of the rheumatic diseases·2012
Same author

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.

Annals of the rheumatic diseases·2012
Same author

European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.

Annals of the rheumatic diseases·2011
Same author

Advances in targeted therapies XII. Preface.

Annals of the rheumatic diseases·2011

Area of Science:

  • Immunology
  • Autoimmune Diseases
  • Therapeutic Development

Background:

  • Autoimmune diseases involve a loss of self-tolerance, leading to immune system attacks on the body's own tissues.
  • T-cell directed therapies, specifically anti-CD4 monoclonal antibodies (CD4-mAb), are being investigated as a strategy to restore self-tolerance.
  • Animal models provide valuable insights into the potential efficacy of these therapeutic approaches.

Purpose of the Study:

  • To evaluate the potential of T-cell directed therapies, particularly CD4-mAb, in reinducing self-tolerance in autoimmune conditions.
  • To assess the capacity of CD4-mAb to prevent and suppress disease activity in relevant animal models.

Main Methods:

  • Utilizing established animal models of human autoimmune diseases.
  • Administering anti-CD4 monoclonal antibodies (CD4-mAb) in both prophylactic and therapeutic settings.
  • Monitoring disease progression and activity in treated versus control groups.

Main Results:

  • CD4-mAb demonstrated efficacy in preventing the onset of autoimmune disease in animal models.
  • Treatment with CD4-mAb was shown to suppress ongoing disease activity in these models.
  • Collagen-induced arthritis, a model for rheumatoid arthritis, was notably responsive to CD4-mAb therapy.

Conclusions:

  • The findings support the potential of CD4-mAb as a viable therapeutic strategy for autoimmune diseases.
  • Reinducing self-tolerance via T-cell modulation is a feasible approach for managing these conditions.
  • Further research into CD4-mAb therapies is warranted for human autoimmune disease treatment.

Related Experiment Videos